Welcome to YLOAN.COM
yloan.com » Marketing » Non - Small Cell Lung Cancer (nsclc) - Drug Pipeline Analysis And Market Forecasts To 2015
Marketing Advertising Branding Careers-Employment Change-Management Customer Service Entrepreneurialism Ethics Marketing-Direct Negotiation Outsourcing PR Presentation Resumes-Cover-Letters Sales Sales-Management Sales-Teleselling Sales-Training Strategic-Planning Team-Building Top7-or-Top10-Tips Workplace-Communication aarkstore corporate advantages development collection global purchasing rapidshare grinding wildfire shipping trading economy wholesale agency florida attorney strategy county consumer bills niche elliptical

Non - Small Cell Lung Cancer (nsclc) - Drug Pipeline Analysis And Market Forecasts To 2015

Description

Description

The industry analysis specialists new report, Non-Small Cell Lung Cancer (NSCLC) - Drug Pipeline Analysis and Market Forecasts to 2015 is an essential source of information and analysis on the global NSCLC disease market. The report identifies the key trends shaping and driving the global NSCLC disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global NSCLC disease sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts.

Estimates the global NSCLC disease market to be $2.8 billion in 2008. It is forecast to grow at a compound annual growth rate (CAGR) of 13.5% for the next seven years to reach $6.8 billion by 2015. This growth is primarily attributed to increased disease population and strong pipeline with more emerging therapies. The available treatment options are moderately successful in meeting the market demand. There exists a significant market potential to be tapped for any new entrant that will cater to the unmet needs. There is enormous opportunity for any drug that would offer better efficacy provided by the current players with increased safety than the current products.

Finds that that the emerging therapies in pipeline are expected to increase the competition. Emerging therapies have gained a positive perception among the physicians due to increased efficacy, safety and overall survival. The strong pipeline leads to the stiff competition in the NSCLC market and the existing market leaders need to be prepared to manage this expected dynamism in competition as there is a race to reach the blockbuster drug status.

Scope of the Report

The report analyzes market opportunities and challenges for the global NSCLC disease market. Its scope includes

Annualized global NSCLC disease market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.

* Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.

* Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes tyrosine kinase inhibitors, microtubules, protein kinase inhibitors, cell division inhibitors, ERBB3 antagonist, DNA and RNA synthesis inhibitors, C-Met or ALK Inhibitors, glutathione S-transferase binders, growth and survival of MM cells inhibitors, HER2 dimerization inhibitors, antiangiogenesis inhibitors, cyclooxygenase-2 (COX-2) inhibitors, Pan Bcl-2 inhibitors and MUC1 tumor-associated antigens etc.

* Analysis of the current and future market competition in the global NSCLC disease market. Key market players covered are F. Hoffmann-La Roche Ltd, Pfizer Inc., Novartis AG, Sanofi-aventis, Boehringer Ingelheim GmbH, and Abraxis BioScience, Inc.

* Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

* Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with NSCLC disease.

For more information, please visit:

http://www.aarkstore.com/reports/Non-Small-Cell-Lung-Cancer-NSCLC-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015-40532.html

Or email us at press@aarkstore.com or call +919272852585

Aarkstore Enterprise

Tel : +912227453309

Mobile No: +919272852585

Email : contact@aarkstore.com


Website : http://www.aarkstore.com

Blog: http://blogs.aarkstore.com/

Follow us on twitter: http://twitter.com/aarkstoredotcom

by: Aarkstore Enterprise
Global Consumer Trends: Profiting In 2010 And Beyond - Market Research Report On Aarkstore Enterpris Spreadtrum Communications Q1 revenue increased 5 times the net profit of 6.6 million U.S. dollars The Marketing Grinch Christmas Sale – Worth it? Global Markets: European Stocks Down; Eyes On Banks, Ash Cloud - Wall Street Journal The Marketing Grinch Christmas Sale - My Thoughts How Do You Make Money Online with Affiliate Marketing? Ovarian Cancer - Drug Pipeline Analysis And Market Forecasts To 2016---aarkstore Enterprise Market Profiting From Consumer Mega -trends In Asia Pacific: Convenience - Market Research Report On Aarkst Xianyang City, Shaanxi Province rose steadily green leafy vegetable market tight class Possibility Of Making Big Money In The Stock Market BlackWhiteMingle- The interracial singles online dating site , no scams Atopic Dermatitis - Drug Pipeline Analysis And Market Forecasts To 2016---aarkstore Enterprise Fbf Diet Scam
print
www.yloan.com guest:  register | login | search IP(216.73.216.142) California / Anaheim Processed in 0.018428 second(s), 7 queries , Gzip enabled , discuz 5.5 through PHP 8.3.9 , debug code: 47 , 4136, 66,
Non - Small Cell Lung Cancer (nsclc) - Drug Pipeline Analysis And Market Forecasts To 2015 Anaheim